Literature DB >> 21824780

Discovery of a novel series of selective HCN1 blockers.

Kelly J McClure1, Michael Maher, Nancy Wu, Sandra R Chaplan, William A Eckert, Dong H Lee, Alan D Wickenden, Michelle Hermann, Brett Allison, Natalie Hawryluk, J Guy Breitenbucher, Cheryl A Grice.   

Abstract

The discovery of a series of novel, potent, and selective blockers of the cyclic nucleotide-modulated channel HCN1 is disclosed. Here we report an SAR study around a series of selective blockers of the HCN1 channel. Utilization of a high-throughput VIPR assay led to the identification of a novel series of 2,2-disubstituted indane derivatives, which had moderate selectivity and potency at HCN1. Optimization of this hit led to the identification of the potent, 1,1-disubstituted cyclohexane HCN1 blocker, 2-ethoxy-N-((1-(4-isopropylpiperazin-1-yl)cyclohexyl)methyl)benzamide. The work leading to the discovery of this compound is described herein.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824780     DOI: 10.1016/j.bmcl.2011.07.051

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

Review 1.  Exploring HCN channels as novel drug targets.

Authors:  Otilia Postea; Martin Biel
Journal:  Nat Rev Drug Discov       Date:  2011-11-18       Impact factor: 84.694

2.  Intramolecular Hydrogen Bond Expectations in Medicinal Chemistry.

Authors:  Fabrizio Giordanetto; Christian Tyrchan; Johan Ulander
Journal:  ACS Med Chem Lett       Date:  2017-01-18       Impact factor: 4.345

3.  Alkylphenol inverse agonists of HCN1 gating: H-bond propensity, ring saturation and adduct geometry differentially determine efficacy and potency.

Authors:  Rebecca L Joyce; Nicole P Beyer; Georgia Vasilopoulos; Kellie A Woll; Adam C Hall; Roderic G Eckenhoff; Dipti N Barman; J David Warren; Gareth R Tibbs; Peter A Goldstein
Journal:  Biochem Pharmacol       Date:  2019-02-13       Impact factor: 5.858

4.  HCN1 channels as targets for anesthetic and nonanesthetic propofol analogs in the amelioration of mechanical and thermal hyperalgesia in a mouse model of neuropathic pain.

Authors:  Gareth R Tibbs; Thomas J Rowley; R Lea Sanford; Karl F Herold; Alex Proekt; Hugh C Hemmings; Olaf S Andersen; Peter A Goldstein; Pamela D Flood
Journal:  J Pharmacol Exp Ther       Date:  2013-04-02       Impact factor: 4.030

5.  Seizures, behavioral deficits, and adverse drug responses in two new genetic mouse models of HCN1 epileptic encephalopathy.

Authors:  Andrea Merseburg; Jacquelin Kasemir; Eric W Buss; Felix Leroy; Tobias Bock; Alessandro Porro; Anastasia Barnett; Simon E Tröder; Birgit Engeland; Malte Stockebrand; Anna Moroni; Steven A Siegelbaum; Dirk Isbrandt; Bina Santoro
Journal:  Elife       Date:  2022-08-16       Impact factor: 8.713

6.  2,4-Dibromo-2,3-dihydro-1H-inden-1-yl acetate.

Authors:  Ismail Celik; Mehmet Akkurt; Makbule Yilmaz; Ahmet Tutar; Ramazan Erenler; Canan Kazak
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-05-26

7.  Intrinsic electrophysiological properties of entorhinal cortex stellate cells and their contribution to grid cell firing fields.

Authors:  Hugh Pastoll; Helen L Ramsden; Matthew F Nolan
Journal:  Front Neural Circuits       Date:  2012-04-24       Impact factor: 3.492

Review 8.  Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels.

Authors:  Daniel C Cook; Peter A Goldstein
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

9.  Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect?

Authors:  Kelly Ann Aromolaran; Peter A Goldstein
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

10.  2,5-Dibromo-indan-1-ol.

Authors:  Ismail Celik; Mehmet Akkurt; Makbule Yilmaz; Ahmet Tutar; Ramazan Erenler; Santiago García-Granda
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.